Iovance Biotherapeutics Management
Management criteria checks 4/4
Iovance Biotherapeutics' CEO is Frederick Vogt, appointed in Jul 2017, has a tenure of 6.83 years. total yearly compensation is $4.79M, comprised of 14.4% salary and 85.6% bonuses, including company stock and options. directly owns 0.051% of the company’s shares, worth $1.96M. The average tenure of the management team and the board of directors is 3.3 years and 7.8 years respectively.
Key information
Frederick Vogt
Chief executive officer
US$4.8m
Total compensation
CEO salary percentage | 14.4% |
CEO tenure | 6.8yrs |
CEO ownership | 0.05% |
Management average tenure | 3.3yrs |
Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Aug 04Iovance: TIL Cell Therapy Set To Prove Itself
Jul 11Iovance: Onward To Approval
Apr 20Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside
Mar 25Iovance Biotherapeutics: Uncertainty And Opportunity
Dec 05Iovanve Biotherapeutics (IOVA) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 16Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21
Jun 07Iovance: Down And Rebound
May 30Here's Why We're Not Too Worried About Iovance Biotherapeutics' (NASDAQ:IOVA) Cash Burn Situation
Mar 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$5m | US$692k | -US$444m |
Sep 30 2023 | n/a | n/a | -US$433m |
Jun 30 2023 | n/a | n/a | -US$419m |
Mar 31 2023 | n/a | n/a | -US$412m |
Dec 31 2022 | US$5m | US$650k | -US$396m |
Sep 30 2022 | n/a | n/a | -US$390m |
Jun 30 2022 | n/a | n/a | -US$376m |
Mar 31 2022 | n/a | n/a | -US$358m |
Dec 31 2021 | US$8m | US$471k | -US$342m |
Sep 30 2021 | n/a | n/a | -US$311m |
Jun 30 2021 | n/a | n/a | -US$284m |
Mar 31 2021 | n/a | n/a | -US$265m |
Dec 31 2020 | US$3m | US$418k | -US$260m |
Sep 30 2020 | n/a | n/a | -US$255m |
Jun 30 2020 | n/a | n/a | -US$246m |
Mar 31 2020 | n/a | n/a | -US$230m |
Dec 31 2019 | US$2m | US$398k | -US$198m |
Sep 30 2019 | n/a | n/a | -US$167m |
Jun 30 2019 | n/a | n/a | -US$151m |
Mar 31 2019 | n/a | n/a | -US$134m |
Dec 31 2018 | US$514k | US$375k | -US$124m |
Sep 30 2018 | n/a | n/a | -US$117m |
Jun 30 2018 | n/a | n/a | -US$105m |
Mar 31 2018 | n/a | n/a | -US$98m |
Dec 31 2017 | US$860k | US$326k | -US$92m |
Compensation vs Market: Frederick's total compensation ($USD4.79M) is about average for companies of similar size in the US market ($USD6.67M).
Compensation vs Earnings: Frederick's compensation has been consistent with company performance over the past year.
CEO
Frederick Vogt (49 yo)
6.8yrs
Tenure
US$4,794,680
Compensation
Dr. Frederick G. Vogt, PhD, Esq., JD, serves as an Interim CEO & President at Iovance Biotherapeutics, Inc. since June 19, 2021. He has been the General Counsel at Iovance Biotherapeutics, Inc. since July...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Interim CEO | 6.8yrs | US$4.79m | 0.051% $ 2.0m | |
CFO, Principal Accounting Officer & Treasurer | 3.4yrs | US$1.71m | 0.0087% $ 338.3k | |
Chief Operating Officer | 3.2yrs | US$1.59m | 0.014% $ 527.8k | |
Chief Medical Officer | 4.8yrs | US$1.77m | 0.015% $ 590.8k | |
Vice President of Investor Relations & Public Relations | no data | no data | no data | |
Senior Vice President of Human Resources | 2.1yrs | no data | no data | |
Chief Business Officer | 5.2yrs | no data | no data | |
Executive Vice President of Commercial | no data | no data | no data | |
Executive VP of Regulatory Strategy & Translational Medicine | 2.2yrs | no data | no data | |
Senior VP & Head of Digital and Information Technology | 2.1yrs | no data | no data | |
Senior Vice President of Quality | 3.3yrs | no data | no data | |
Senior Vice President of Research | 2.1yrs | no data | no data |
3.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: IOVA's management team is considered experienced (3.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 7.9yrs | US$240.00k | 10.03% $ 389.6m | |
Independent Director | 12.8yrs | US$500.75k | 0.20% $ 7.9m | |
Independent Director | 6.2yrs | US$744.99k | 0.050% $ 2.0m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 9.3yrs | US$489.99k | 0.0027% $ 104.1k | |
Independent Chairman of the Board | 7.8yrs | US$933.48k | 0.019% $ 749.6k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 4.9yrs | US$489.99k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
7.8yrs
Average Tenure
62.5yo
Average Age
Experienced Board: IOVA's board of directors are considered experienced (7.8 years average tenure).